On Oct. 8, Keybanc analyst John Vinh maintained Micron Technology with an Overweight and lowered the price target from $145 ...

Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...

The U.S. government announced quality ratings for 2025 Medicare health and prescription drug plans on Thursday, the first ...

Barclays upgrades CVS Health to Overweight, citing gains in pharmacy market share and potential upside from CostVantage. CVS is expected to recover 200 basis points in Medicare margins by 2026, ...

Key Takeaways A higher-than-anticipated report on consumer inflation sent U.S. equities lower at midday.Solar power company ...

Analysts upgraded shares of the healthcare company to Overweight from Equal Weight and raised their price target to $82.

CVS Health (CVS) stock gained as Barclays upgraded the company, citing a compelling path to margin recovery in its Medicare ...

CVS Health (CVS – Research Report) received a Buy rating and an $82.00 price target from Barclays analyst Andrew Mok CFA today. The ...

CVS Health is laying off approximately 2,900 employees across its company and impacted positions are “primarily corporate ...

The drugstore chain's board has hired bankers to help review options for the company, including a potential breakup. Shares ...

Virginia Drosos plans to retire in November after serving at the helm of the jewelry company since 2017. Publishers turn to subscriptions in search of new revenue, entering a crowded field.

CVS is planning to cut about 2,900 jobs in an effort to slash costs, the company said Tuesday. The job cuts at the company add to the 5,000 or so layoffs last year.